Perspectives on Novel Antibody Platforms in DLBCL
Chair & Presenters, Grzegorz (Greg) Nowakowski, MD, Paolo F. Caimi, MD, and Stephen J. Schuster, MD, discuss diffuse large B-cell lymphoma in this CME/MOC activity titled “Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/ENP865. CME/MOC credit will be available until January 8, 2024.
Perspectives on Novel Antibody Platforms in DLBCL
Теги
Grzegorz (Greg) Nowakowski MDPaolo F Caimi MDStephen J Schuster MDCMEMOCmededoncologyhematologyDLBCLlymphomaantibody therapycellular therapyimmunotherapyloncastuximab tesirinepolatuzumab vedotintafasitamabaxicabtagene ciloleucellisocabtagene maraleuceltisagenlecleucelR/R DLBCLlenalidomidebispecific antibodiesepcoritamabsafety profileLONCA-RglofitamabPOLA-BRCAR-TBTKiibrutinibpractical considerationsmosunetuzumabNHLR/R NHL
